Through years of development, our team has built a comprehensive oncology portfolio that covers the full cycle of cancer management, addressing needs and challenges from early screening, diagnosis & monitoring, and biopharma development services. While continuously carrying out scientific and technological innovation, we efficiently transform these breakthroughs into clinical applications, which have served tens of thousands of patients, and dozens of scientific research institutions and pharmaceutical enterprises across China. See our journey below.



Genetron Health begins strategic partnership with Chia Tai Tianqing (CTTQ) Pharmaceutical Group.


Genetron Health releases new prospective cohort study data of HCCscreen for early liver cancer screening.


Genetron Health receives CE Mark for 8-Gene Lung Cancer Assay.


Genetron Health receives full marks under the NCCL external quality assessment of NGS-based comprehensive genomic profiling for solid tumors, ranking first among the 63 laboratories nationwide.


Genetron Health’s early precision lung cancer diagnosis and treatment project, a joint initiative with the West China Hospital of Sichuan University, won the second prize of China’s National Science and Technology Progress Award.


Genetron Health signed a collaboration agreement with AstraZeneca R&D China for the joint development in China of NGS-based tumor-informed (personalized) MRD tests for various solid tumor types.


Genetron Health’s liver cancer screening results and technology findings are included in the expert consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma – submitted by the Infectious Disease Prevention and Control Division of the Chinese Preventive Medicine Association.


Genetron Health’s multi-gene mutation detection kit Onco PanScan obtains CE Mark


Laboratory in Maryland is established



Genetron Health announces companion diagnostic collaboration agreement with HUTCHMED’s ORPATHYS® for NSCLC

Genetron Health’s proprietary Mutation Capsule technology was granted an invention patent (201910983038.8) by the China National Intellectual Property Administration.


Genetron Health’s Beijing clinical laboratory became the only laboratory nationwide to receive full marks in the NCCL EQA pre-research project of bioinformatics analysis on tumor mutation burden testing with dual sequencing platforms.

Genetron Health's latest technological advances in precision oncology were highlighted in the Nature Index 2022 Big 5 Science Nations.


Genetron Health Receives CE Mark for Human B Lymphocyte Minimal Residual Disease Detection Kit Seq-MRD®


Genetron Health receives CE Mark for its FusionScan Plus Kit for human multi-genes.

Genetron Health receives CAP Accreditation for its Maryland Laboratory.


Genetron Health's early liver cancer screening technology was incorporated into the China Guideline for Liver Cancer Screening (2022, Beijing).


Genetron Health signed contracts with AstraZeneca and Roche respectively to each build a precision oncology ecosystem.

Two new liquid biopsy products, GENETRON MRD and Onco Sonar, were launched during the Annual Meeting of the Chinese Society of Clinical Oncology.


A research paper based on Genetron Health's early cancer screening technology, Mutation Capsule Plus, was published by Science Translational Medicine.